EcoDrugPlus

Protein Kinase D1

Ensembl ID : ENSEEEG00000002449
Gene Symbol: PRKD1
4 Cross references
214 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSEEEG00000009669
Gene Symbol: PRKD3
4 Cross references
207 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSEEEG00000022404
Gene Symbol: PRKD3
4 Cross references
218 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSEEEG00000024659
Gene Symbol: PRKDC
4 Cross references
187 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSEEEG00000018736
Gene Symbol: PPP3CA
2 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSEEEG00000013275
Gene Symbol: PTK2
4 Cross references
243 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSEEEG00000010024
Gene Symbol: PTK2B
4 Cross references
142 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSEEEG00000023948
Gene Symbol: PTK2BB
4 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSEEEG00000010619
Gene Symbol: PTPN11A
4 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSEEEG00000020457
Gene Symbol: PTPRB
2 Cross references
201 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSEEEG00000020418
Gene Symbol: PTPRB
4 Cross references
194 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSEEEG00000010836
Gene Symbol: LOC113568043
4 Cross references
265 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).